X

Vous n'êtes pas connecté

Maroc Maroc - DRUGS.COM - Clinical Trials News - 04/Sep 22:09

Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema

RAHWAY, N.J.--(BUSINESS WIRE) September 4, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and EyeBio, a wholly-owned subsidiary of Merck & Co., Inc., Rahway, N.J., USA, today announced the initiation of the...

Articles similaires

Sorry! Image not available at this time

Merck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug

zacks.com - 05/Sep 15:21

The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss.

Twiggy’s Tenmile to become largest shareholder of Lumos Diagnostics

stockhead.com.au - 05/Sep 03:03

A wholly owned subsidiary of Andrew and Nicola Forest’s private investment vehicle Tattarang is set to become the largest shareholder ...

Twiggy’s Tenmile to become largest shareholder of Lumos Diagnostics

stockhead.com.au - 05/Sep 03:03

A wholly owned subsidiary of Andrew and Nicola Forest’s private investment vehicle Tattarang is set to become the largest shareholder ...

Sorry! Image not available at this time

Perfetti Van Melle Nigeria Limited Ongoing Job Recruitment – Apply Here!

joblistnigeria.com - 04/Sep 08:00

Perfetti Van Melle Nigeria Limited is a wholly owned subsidiary of Perfetti Van Melle group, one of the worlds largest manufacturers and distributors...

Sorry! Image not available at this time

Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

drugs.com - 07/Sep 06:09

BASKING RIDGE, N.J. & RAHWAY, N.J., September 7, 2024 – Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01...

Sorry! Image not available at this time

Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

drugs.com - 07/Sep 06:09

BASKING RIDGE, N.J. & RAHWAY, N.J., September 7, 2024 – Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01...

Sorry! Image not available at this time

Convoy Global Holdings Limited successfully defends another shareholder derivative action in Hong Kong

harneys.com - 09/Sep 18:16

On 21 August 2024, the High Court of Hong Kong, Court of First Instance delivered its decision in the latest proceedings concerning Convoy Global...

NPC Resources to dispose of indirectly-owned loss-making subsidiary for RM29mil

thestar.com.my - 02/Sep 11:02

PETALING JAYA: NPC Resources Bhd is disposing of its indirectly-owned wholly-owned subsidiary, PT Enggang Alam Sawita (EAS), to PT Bayan Resources Tbk...